---
title: "NeuroSense announces shareholder letter availability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295808294.md"
description: "NeuroSense Therapeutics released a shareholder letter highlighting FDA clearance for the Phase 3 PARAGON ALS study, targeting ~300 participants. Financing remains ongoing with strategic partners. A New Drug Submission to Canada is targeted for December 2026 based on Phase 2b data. The company is addressing Nasdaq compliance via potential reverse splits and noted insider investments of USD 600,000 in April 2026."
datetime: "2026-08-13T13:36:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295808294.md)
  - [en](https://longbridge.com/en/news/295808294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295808294.md)
---

# NeuroSense announces shareholder letter availability

-   NeuroSense Therapeutics released a CEO letter to shareholders outlining near-term priorities for PrimeC in ALS. \* FDA clearance received to start the Phase 3 PARAGON study; planned enrollment about 300 participants, mainly in the US. \* Financing to run PARAGON has taken longer than expected; talks continue with strategic partners, investors, grants, non-dilutive sources. \* Canada regulatory path pursued; New Drug Submission for PrimeC targeted for December 2026, based on Phase 2b PARADIGM data. \* Nasdaq compliance efforts focus on bid-price; board authority sought for a 1-for-4 to 1-for-40 reverse split if needed. \* CEO Alon Ben-Noon, CFO Or Eisenberg invested USD 200,000 each in April 2026; combined with another investor totaled USD 600,000. \* here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans](https://longbridge.com/en/news/295817302.md)
- [NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts](https://longbridge.com/en/news/295819565.md)
- [NeuroSense Issues CEO Letter to Shareholders | NRSN Stock News](https://longbridge.com/en/news/295808583.md)
- [Tinde Sparebank releases Q2 2026 interim report](https://longbridge.com/en/news/295802190.md)
- [Diageo announces BRL 0.32 per unit distribution for Q3 2026](https://longbridge.com/en/news/295964479.md)